Insiders Advisor
  • Stocks
  • World News
  • Business
  • Politics
  • Stocks
  • World News
  • Business
  • Politics

Insiders Advisor

Business

Hims & Hers Health says it will offer compounded GLP-1 injections

by May 21, 2024
May 21, 2024
Hims & Hers Health says it will offer compounded GLP-1 injections

Digital pharmacy startup Hims & Hers Health is introducing access to compounded GLP-1 weight loss injections, the company announced Monday.

Shares of the company surged.

The company, which offers a range of direct-to-consumer treatments for conditions like erectile dysfunction and hair loss, launched a weight loss program in December. But GLP-1 medications — such as Ozempic and Wegovy, which have skyrocketed in popularity — were not previously offered as part of that program.

Customers can access the compounded GLP-1 medications via a prescription from a licensed health-care provider on the Hims & Hers platform. Hims & Hers said it plans to make branded GLP-1 medications available to its customers once supply is consistently available.

The company’s oral medication kits start at $79 a month, and its compounded GLP-1 injections will start at $199 a month.

Even before it added compounded GLP-1s to its portfolio, Hims & Hers said in its fourth-quarter earnings report that it expects its weight loss program to bring in more than $100 million in revenue by the end of 2025. The company plans to offer updated guidance in its next earnings report.

The GLP-1 market, dominated so far by pharmaceutical giant Novo Nordisk, has faced supply constraints in recent months as the drugs get expanded approval from health regulators and increased health coverage.

GLP-1s mimic a hormone produced in the gut to tamp down a person’s appetite and regulate their blood sugar. When those medications are in shortage, certain manufacturers can prepare a compounded version if they meet U.S. Food and Drug Administration requirements.

The FDA does not review the safety and efficacy of compounded products, which are custom-made alternatives to brand drugs designed to meet a specific patient’s needs.

In a January release, the FDA said patients should not use a compounded GLP-1 drug if an approved drug, such as Wegovy, is available.

Hims & Hers CEO Andrew Dudum told CNBC that the company is “confident” that customers will be able to access a consistent supply of the compounded medications.

Dudum said Hims & Hers has spent the last year learning about the GLP-1 supply chain and has partnered with one of the largest generic manufacturers in the country that has FDA oversight.

“We have a certain degree of exclusivity with that facility that will guarantee our consumers consistent volume and supply,” he said.

This post appeared first on NBC NEWS
previous post
Wendy’s will offer $3 breakfast deal as rivals such as McDonald’s test value meals to drive sales
next post
MTG responds to House Dem planning to hawk merchandise using ‘bleach blonde’ insult used against her

Related Posts

Google forcing some remote workers to come back...

April 24, 2025

How Volvo landed a cheap Chinese EV on...

April 26, 2024

Airbus could prioritize deliveries to non-U.S. customers if...

February 20, 2025

Fox reveals plans to launch subscription streaming service...

February 5, 2025

Reddit co-founder Alexis Ohanian takes minority stake in...

May 16, 2025

Trump Media auditor charged by SEC with ‘massive...

May 5, 2024

Universal’s new Epic Universe park set to generate...

April 16, 2025

Forever 21 seeks rent concessions as fast-fashion brand...

June 24, 2024

Self-driving Cruise vehicle accused of nearly hitting kids...

February 15, 2024

Trump Media stock erases all gains since it...

April 9, 2024

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Latest News

    • ‘Game changer’: Bipartisan senators gunning for Russia sanctions ready to give Trump runway

      July 15, 2025
    • Constitutional scholar uses Biden autopen to flip Dems’ ‘democracy’ script against them: ‘Scandal’

      July 15, 2025
    • Senate GOP braces for test vote on Trump’s $9.4B clawback package

      July 15, 2025
    • Anthony Bernal: Who is Jill Biden’s top aide ordered to testify about alleged cover-up?

      July 15, 2025
    • Hegseth abruptly pulls Pentagon officials from ‘globalist’ Aspen conference

      July 15, 2025
    • Mike Waltz faces post-Signalgate ‘brutal’ grilling from Dems in UN ambassador hearing

      July 15, 2025

    Categories

    • Business (1,306)
    • Politics (6,388)
    • Stocks (904)
    • World News (460)
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: insidersadvisor.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 insidersadvisor.com | All Rights Reserved